ClinicalTrials.gg
RecruitingNCT05187832Updated Feb 27, 2026

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

A Phase 1 interventional study of AND019 PO QD in Advanced or Metastatic Breast Cancer, sponsored by Kind Pharmaceuticals LLC. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Kind Pharmaceuticals LLC · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

02

Conditions studied

  • Advanced or Metastatic Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 61 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Kind Pharmaceuticals LLC is the lead sponsor of 12 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. women defined as NCCN guideline at the time of .
  2. Histological or cytological confirmation of advanced or ER+/- breast cancer women who failed standard therapy or for which no standard therapy exists.
  3. Prior therapy:

    1. No more than 1 for advanced breast cancer
    2. Recurrence or progression on at least one line of endocrine therapy in the advanced or metastatic disease setting and derived a clinical benefit from the endocrine therapy: Recurred or progressed while being treated with endocrine therapy for a duration of at least 24 months, or progressed under endocrine therapy for more than 6 months in the advanced or metastatic setting
  4. score 0-1.
  5. Minimum of a least 3 months as determined by the Investigator.
  6. Evaluable disease per 1.1; for patients consent to tissue , disease suitable for tumor biopsy.
  7. Sufficient bone marrow reserve and organ function.

Key Exclusion Criteria:

  1. Previous treatment with any SERDs.
  2. Patient any central nervous system metastasis.
  3. Prior antitumor therapies:

    1. Received chemotherapies within 3 weeks before the first dose.
    2. Received systemic radiotherapy within 3 weeks before the first dose, or local radiotherapy within 7 days before the first dose
    3. Received other anti-tumor therapy such as endocrine therapy, immunotherapy, and target therapy within 3 weeks or 5 half-lives of the drug before the first dose of the study drug
    4. For bone metastasis, bisphosphonates and local remission therapy are allowed (7 days washout for local radiation therapy).
  4. Patient who has participated in any other clinical trials for drugs or treatments within 5 half-lives for a prior drug or 2 weeks from use of an investigational device prior to the first dose of study drug.
  5. Patient who had major surgery or significant trauma within 4 weeks prior to the first dose of study drug (excluding needle biopsy), or has scheduled surgery during the study period.
  6. Patient with serous unhealable wounds/ulcers/fractures within 4 weeks prior to the first dose of study drug.
  7. Patient with adverse reactions to previous anti-tumor treatments who have not yet recovered to grade ≤1 according to v5.0. (except for toxicities without safety risks as judged by Investigator, such as alopecia, grade 2 peripheral neuropathy etc.)
  8. Patient who has used strong inhibitors or strong inducers of , or grapefruit or grapefruit juice within 4 weeks prior to the first dose of study drug.
  9. Patient unable to be administered oral medications or any condition that seriously affect digestion in the gastrointestinal tract at the judgement of the Investigator.
  10. Patient with active infection within 1 week prior to the first dose of study drug, and currently need systemic anti-infective treatment.
  11. Patient has a known history of the following: infection without effective antiretroviral therapy (ART) or acceptable immune function, or syphilis infection, or positive HBV or needs prophylaxis therapy or suppressive antiviral therapy before dosing, or has an infection that hasn't completed curative antiviral treatment or with unacceptable viral load.
  12. Patient has active cardiac disease or a history cardiac dysfunction.
  13. Patient with third spacing that cannot be controlled clinically and is not suitable for the study by the Investigator's judgment.
  14. Patient with known history of drug abuse.
  15. Patient with mental disorder that, in the opinion of the Investigator, could lead to poor compliance with required study procedures.
  16. Patient that cannot tolerate venous blood sampling.
  17. Known to have other within the past 5 years, and is progressing or requires active treatment (except skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ who have received potentially radical treatment)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (estimated)

Study arms

  • Experimental
    AND019 single dose escalation and expansion

    Subjects will be administrated with AND019 capsule PO QD from 20 mg to 400 mg during Part 1, and 2 dose groups will be selected for dose expansion study

    Drug: AND019 PO QD

Interventions

  • DrugAND019 PO QD

    AND019 administrated as oral capsule once per day for 28 days for each cycle

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events by severity, according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0

    Number of participants with adverse events

    Time frame: From baseline to 12 weeks after the last dose of study treatment (up to 25 months)

  2. PK study of AND019

    Plasma concentration of AND019 over time

    Time frame: At predefined timepoints at Day 1, Day 8, Day 15, and Day 22 of Cycle 1, and Day 1 of each cycle starting from Cycle 2 (each cycle is 28 days)

Secondary outcomes

  1. Determine the RP2D

    To observe the dose limiting toxicity (DLT) and maximum tolerated dose MTD to determine RP2D.

    Time frame: From baseline to up to the end of Cycle 1 (each cycle is 28 days)

  2. Percentage of Participants with Objective Response

    ORR is defined as a complete response or partial response on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Baseline and every 8 weeks from Cycle 1 Day 1 until Week 24, and then every 12 weeks until end of study treatment (up to 24 months) (each cycle is 28 days)

  3. Clinical Benefit Rate

    CBR is defined as the percentage of participants achieving either of the following: confirmed complete response or partial response (as determined by the investigator according to RECIST v1.1); or the first occurrence of progressive disease after 24 weeks of study treatment.

    Time frame: Baseline and every 8 weeks from Cycle 1 Day 1 until Week 24 (each cycle is 28 days)

  4. Duration of Response

    DoR is defined as the percentage of participants achieving either of the following: confirmed complete response or partial response.

    Time frame: From the first occurrence of a documented objective response until first observation of disease progression or death from any cause on study, whichever occurs first (up to 24 months)

Other outcomes

  1. Progression free survival

    PFS is defined as the time from treatment start date until objective tumor progression (PD) or death whichever comes first

    Time frame: From treatment start date until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

  2. PD study of AND019 in blood samples

    Change from baseline in therapy resistant markers by liquid biopsy

    Time frame: At predefined timepoints at baseline, Cycle 1 Day 15, Cycle 2 Day 1, and End of Treatment (up to 2 years) (each cycle is 28 days).

  3. PD study of AND019 in tissue samples

    Change from baseline in therapy resistant markers by tissue biopsy

    Time frame: At predefined timepoints at baseline and between Cycle 2 Day 1 to Cycle 3 Day 28 (each cycle is 28 days)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Nov 2026, 49 months after the start.

Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 49 months is above that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Jan 12, 2022
StartActual
Oct 5, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05187832
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Oct 5, 2022
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Yusha Zhu, MD PhD
Contact
yushazhu@kindpharmaceutical.com
6467252552
Yusha Zhu, MD PhD
study director · Kind Pharmaceuticals LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion